Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions by María de Lourdes Mora-García et al.
de Lourdes Mora‑García et al. J Transl Med  (2016) 14:302 
DOI 10.1186/s12967‑016‑1057‑8
RESEARCH
Mesenchymal stromal cells derived 
from cervical cancer produce high amounts 
of adenosine to suppress cytotoxic T 
lymphocyte functions
María de Lourdes Mora‑García1, Rosario García‑Rocha1,2, Omar Morales‑Ramírez2, Juan José Montesinos3, 
Benny Weiss‑Steider1, Jorge Hernández‑Montes1, Luis Roberto Ávila‑Ibarra1,2, Christian Azucena Don‑López1, 
Marco Antonio Velasco‑Velázquez4, Vianey Gutiérrez‑Serrano1,2 and Alberto Monroy‑García1,2,5*
Abstract 
Background: In recent years, immunomodulatory mechanisms of mesenchymal stem/stromal cells (MSCs) from 
bone marrow and other “classic” sources have been described. However, the phenotypic and functional properties of 
tumor MSCs are poorly understood. The aim of this study was to analyze the immunosuppressive capacity of cervical 
cancer‑derived MSCs (CeCa‑MSCs) on effector T lymphocytes through the purinergic pathway.
Methods: We determined the expression and functional activity of the membrane‑associated ectonucleotidases 
CD39 and CD73 on CeCa‑MSCs and normal cervical tissue‑derived MSCs (NCx‑MSCs). We also analyzed their immu‑
nosuppressive capacity to decrease proliferation, activation and effector cytotoxic T (CD8+) lymphocyte function 
through the generation of adenosine (Ado).
Results: We detected that CeCa‑MSCs express higher levels of CD39 and CD73 ectonucleotidases in cell membranes 
compared to NCx‑MSCs, and that this feature was associated with the ability to strongly suppress the prolifera‑
tion, activation and effector functions of cytotoxic T‑cells through the generation of large amounts of Ado from the 
hydrolysis of ATP, ADP and AMP nucleotides.
Conclusions: This study suggests that CeCa‑MSCs play an important role in the suppression of the anti‑tumor 
immune response in CeCa through the purinergic pathway.
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Background
Mesenchymal stem/stromal cells (MSCs) are multipo-
tent cells that can be obtained from various mature tis-
sues and are characterized by a wide range of properties, 
including the ability to adhere to plastic; the simultane-
ous expression of CD73, CD90, and CD105; and the lack 
of or reduced expression of specific hematopoietic cell 
markers such as CD14, CD31, CD34, CD45 and HLA-DR 
[1, 2]. They can differentiate into multiple cell types, 
including osteocytes, chondrocytes, adipocytes, fibro-
blasts, myoblasts, oocytes, cardiomyocytes, hepatocytes, 
tenocytes, different epithelial cells (i.e., lung, intestine, 
kidney, and spleen), and even neurons [3–5].
MSCs may be attracted to damaged tissues by inflam-
matory cytokines and chemokines and support tissue 
regeneration and repair [6]. During this process, MSCs 
contact multiple cell types to carry out therapeutic 
effects, either by the release of extracellular vesicles (EV) 
expressing bioactive molecules, such as proteins, lipids, 
and RNA, which might play anti-inflammatory or anti-
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through integrins and intercellular gap junctions [9]. On 
the other hand, the invasive growth of tumors also causes 
inflammation and local tissue damage, attracting MSCs 
to contribute to repair [6]. Approximately 0.01 % of the 
cells within solid tumor tissues are thought to be MSCs 
(T-MSCs) [10]. These T-MSCs stimulate tumor growth 
by stimulating tumor cell proliferation [11], inducing 
epithelial–mesenchymal transition of tumor cells [12], 
prompting the conditions to increase the number of 
cancer stem cells [13], and promoting tumor angiogen-
esis and metastasis [6]. T-MSCs have been isolated and 
characterized from ovarian cancer [14], giant cell tumors 
of bone [15], neuroblastoma [16], osteosarcoma, lipoma 
[17], gastric cancer [18] and cervical cancer (CeCa) [19]. 
In CeCa, our research group was the first to detect the 
presence of MSCs and suggest their involvement in 
tumor cell evasion from the immune response of cyto-
toxic T lymphocytes [19].
In addition, T-MSCs play an important role in the 
immunosuppression of immune effector cells through 
the generation of an anti-inflammatory environment by 
producing Th2-type cytokines (IL-4, IL-5, IL-10) and 
Th3-type cytokines (TGF-β) [6, 13, 20], inducing and 
recruiting regulatory T-cells [21] and producing immu-
nosuppressive factors such as PGE2, IDO and NO [22].
Recently, have been reported that MSCs derived from 
either bone marrow (BM-MSCs) or umbilical cord blood 
(UCB-MSCs), may suppress the response of T lym-
phocytes through the purinergic pathway [23, 24]. In 
this pathway, nucleotides (ATP and ADP) released by 
a variety of cell types in response to stress signals such 
as injury, hypoxia and inflammation, which commonly 
occur in the tumor microenvironment, are jointly hydro-
lyzed by CD39 ectoenzyme (ENTPD1, ectonucleoside 
triphosphate diphosphohydrolase-1, EC 3.6.1.5) to gener-
ate the respective nucleotides. Subsequently, the nucleo-
tides are hydrolyzed by the action of 5′-ectonucleotidase 
ectoenzyme or CD73 (EC 3.1.3.5), converting AMP to 
adenosine (Ado) [25]. Most extracellular Ado signaling 
activities are mediated by G-protein-coupled cell surface 
adenosine receptors (ARs), which are divided into four 
subtypes: A1, A2A, A2B and A3 [26]. Ado may exert its 
immunosuppressive effect on cytotoxic CD8+ T lym-
phocytes (CTLs) through the high-affinity Ado receptor 
A2A [25, 27, 28]. High cAMP production resulting from 
the signaling of this receptor on T-cells inhibits the pro-
liferation and secretion of anti-tumor cytokines, includ-
ing TNF-α and IFN-γ [29, 30], as well as the exocytosis 
of cytolytic granules containing granzymes and perforin 
[31].
The expression of CD39 and CD73 in tumors is mainly 
induced by hypoxia [32] and by the presence of immuno-
suppressive factors such as TGF-β [33]. This expression 
is generally associated with poor prognosis [32, 34]. 
Persistent high-risk human papillomavirus (HR-HPV) 
infection plays an important role in cervical carcinogen-
esis, which is strongly associated with the production of 
immunosuppressive cytokines such as IL-10 and TGF-β. 
Increased IL-10 and TGF-β expression correlates directly 
with the degree of CeCa progression and the suppression 
of the anti-tumor immune response through mechanisms 
that have not yet been fully elucidated [35–37].
To better understand the role that MSCs play in 
tumor biology, in this study, we analyzed the immuno-
suppressive capacity of cervical cancer-derived MSCs 
(CeCa-MSCs) on effector T lymphocytes through the 
purinergic pathway. Interestingly, we found that CeCa-
MSCs express higher levels of CD39 and CD73 ecto-
nucleotidases in cell membranes compared to MSCs 
obtained from normal cervical tissues (NCx-MSCs). This 
feature is associated with the ability to strongly suppress 
the proliferation, activation and effector functions of 
cytotoxic T-cells through the generation of large amounts 
of Ado from the hydrolysis of ATP, ADP and AMP 
nucleotides. This study suggests for the first time that 
CeCa-MSCs play an important role in the suppression 
of the anti-tumor immune response in CeCa through the 
purinergic pathway.
Methods
Mesenchymal stromal cells (MSCs)
The MSCs used in this study were obtained from Normal 
cervix (NCx) tissues, that were obtained from three sub-
jects who had hysterectomy surgery not related to can-
cer, and CeCa samples were obtained from biopsies from 
three patients in stage IIIB. The local ethics committee 
approved these procedures. The CeCa samples intended 
for tissue culture were collected from biopsies sent to the 
Pathology Department for routine diagnosis. NCx- and 
CeCa-derived mesenchymal stromal cells (MSCs) were 
obtained by enzymatic digestion as previously described 
[19], and maintained in low glucose Dulbecco’s Modi-
fied Eagle Medium (DMEM; Gibco Laboratories, Grand 
Island, NY, USA) supplemented with 15  % fetal bovine 
serum (FBS; Gibco), 100  IU/ml penicillin, 100  μg/ml 
streptomycin (Gibco) and 5  mM l-glutamine at 37  °C 
with 5 % CO2.
MSCs were characterized based on the morphologi-
cal, phenotypic and differentiation parameters performed 
according to protocols previously reported by our work-
ing group [19]. FITC, PE or APC-conjugated mono-
clonal antibodies against CD73, CD90 and CD45 (BD 
Biosciences, San Diego, CA, USA) CD105, CD13, CD14, 
(Caltag, Buckingham, UK), HLA-ABC, HLA-DR, CD31 
and CD34 (Invitrogen, Carlsbad, CA, USA) were used for 
immunophenotypic characterizations and analyzed on a 
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CyAN cytometer (Beckman Coulter, Fullerton CA, USA). 
Adipogenic and osteogenic differentiation was induced 
with Stem Cells Kits™ (STEMCELL Technologies, Inc., 
Vancouver, BC, Canada). Adipogenic differentiation 
was determined by visualizing the presence of Oil Red 
O-stained (Sigma-Aldrich, St. Louis, MO, USA) lipid vac-
uoles. Osteogenic differentiation was assessed by alkaline 
phosphatase staining. Chondrogenic differentiation was 
induced with a commercial induction medium (Cam-
brex Bio Science, Walkersville, Inc., Maryland, USA) that 
was supplemented with 10  ng/ml of TGF-β (Cambrex). 
The resulting micromasses were fixed, embedded and 
sliced. Cross-sections were stained with Alcian blue dye 
(Sigma-Aldrich).
Expression of CD39 and CD73 in MSCs
The expression of the ectonucleotidases CD39 and CD73 
in MSC cell membranes was determined by labeling with 
anti-CD39-FITC (eBioscience, San Diego, CA, USA) and 
anti-CD73-PE (BD Bioscience) monoclonal antibodies 
according to the manufacturers’ instructions. Cell analy-
sis was performed from the acquisition of 25,000 events 
in a CyAN cytometer (Beckman Coulter, Fullerton CA, 
USA). In addition, the expression of the ectonucleoti-
dases CD39 and CD73 in MSCs cell membranes was also 
determined by immunocytochemical staining by using 
human anti-CD39 and anti-CD73 mAbs (Novus, Cam-
bridge, UK). Briefly, MSCs grown on glass coverslips to 
semiconfluence, were fixed in 2  % paraformaldehyde 
(Sigma, St. Louis, MO) in PBS for 6 min and permeabi-
lized with 0.01  % Triton X-100 in PBS. Following incu-
bation with 2 % (w/v) bovine serum albumin (Sigma, St. 
Louis, MO), cells were incubated for 1 h with the mAbs. 
Following washing, the coverslips were incubated for 1 h 
with a secondary antibody horseradish peroxidase-con-
jugated goat anti-mouse (DAKO, Carpinteria, USA). The 
development was performed with substrate-chromogen 
solution 3,3′-diaminobenzidine dihydrochloride (DAB) 
for 3–5 min. Secondary antibody alone was included as 
control for the experiments. The nuclei were stained with 
Mayer’s Hematoxylin. Glass coverslips were scanned to 
obtain electronic files. The immunocytochemical stains 
of two stains made independently were digitally analyzed 
using the Aperio CS (San Diego, CA, USA) digital pathol-
ogy equipment.
Hydrolytic activity of CD39 and CD73
Samples containing 105 MSCs were cultured in pres-
ence of 5  mM ATP, ADP or AMP in 200  µl of low glu-
cose DMEM supplemented with 10 % FBS to determine 
the enzymatic activity of the CD39 and CD73 ectonu-
cleotidases. FBS was previously dialyzed with a mem-
brane (molecular weight cutoff of 12 kDa). To inhibit the 
enzymatic activity of CD39 and CD73, MSCs were incu-
bated in the presence of 5 mM specific inhibitors, includ-
ing sodium polyoxotungstate (POM-1, Sigma-Aldrich, 
St Louis, MO, USA) and adenosine 5′-(α,β-methylene) 
diphosphate (APCP, Sigma-Aldrich). After 30  min of 
incubation with each inhibitor, the adenine nucleotides 
ATP, ADP and AMP were added to a final concentration 
of 5 mM. The total culture volumes were 200 µl. Superna-
tant samples were collected every 60 min, and the pres-
ence of Ado was analyzed by thin layer chromatography 
(TLC) and ultra-performance liquid chromatography 
(UPLC) (UPLC aquity, Waters, Milford MA, USA). To 
analyze the samples by TLC, 1 µl of each supernatant was 
loaded on fluorescent plates precoated with gel (What-
man, GE Healthcare, Freiburg, Germany). Samples were 
eluted for 1 h using a mobile phase a mixture composed 
of isobutanol:isoamyl alcohol:ethoxyethanol:ammonia
:water in the ratio 9:6:18:9:15 [38, 39]. ATP, ADP, AMP, 
Ado and inosine (Sigma-Aldrich) at 5 mg/ml were used 
as standards. Finally, the compounds were visualized 
and photographed under an UV transilluminator (UVP 
Biodo-H System, Upland, CA, USA).
Ultra‑performance liquid chromatography (UPLC)
An UPLC system (UPLC acquity, Waters) was used to 
quantify the amount of Ado generated in MSCs cultures 
in the presence of each nucleotide. Quantitative analysis 
of samples using standard quantities of synthetic Ado 
was carried out with Empower 3 software (Waters, USA). 
The mobile phase consisted of 0.5  % acetonitrile, 5  % 
methanol, and 94.5 % sodium acetate buffer 0.25 M, pH 
6.3. Supernatant samples were centrifuged at 13,000 rpm 
and filtered on Amicon membranes with a cutoff of 
3000 Da and subsequently diluted 1:200 with the mobile 
phase mixture. Run conditions were as follows: flow rate 
of 1.0 ml/min, UV detection at 254–260 nm, 2.0 min of 
retention time, room temperature, and a LiChrosfer 5 µm 
RP-18e 100 A (size 125 mm × 4 mm, 5 µm particle size) 
reverse phase column. Ado was quantified by comparing 
the retention time of the sample with that of the synthetic 
Ado used as standard.
In vitro suppression assay for testing T cell proliferation
To determine the suppressive activity of Ado on T-cell 
proliferation, 1  ×  105 CD8+ T-cells isolated from 
peripheral blood mononuclear cells (PBMC) from nor-
mal donors by negative selection (EasySep Enrichment 
Cocktail, Stem Cell Technologies, Vancouver, BC, Can-
ada) were cultured in triplicate in 96-well flat bottom 
plates (Corning, NY, USA) in 100  µl Iscove’s Modified 
Dulbecco’s Medium (IMDM) (Gibco) without phenol 
red, supplemented with 10 % dialyzed FBS. Beads coated 
with anti-CD2/CD3/CD28 antibodies (Miltenyi Biotec 
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GmbH, Bergisch Gladbach, Germany) were added to 
T-cell cultures in a 2:1 ratio of T-cells:beads. To deter-
mine the suppressive capacity of Ado contained in the 
supernatants from MSCs cultured in the presence of 
nucleotides, 20 µl of each supernatant was added to the 
T-cell cultures (total volume of 200  µl) and then incu-
bated at 37  °C and 5  % CO2 for 72  h. Caffeine, a non-
selective antagonist of the Ado receptor, was added to 
some culture plates at a concentration of 300  μM (J.T. 
Baker, Center Valley, PA, USA). In other cases, 1  µM 
ZM241385, a selective antagonist of A2A receptor, or 
ZM241385 (1  μM) plus caffeine (300  μM) were added. 
Lymphocytes stimulated with beads coated with anti-
CD2/CD3/CD28 antibodies alone or in the presence of 
synthetic Ado (500 μM), caffeine (300 μM), Ado:caffeine 
(500 μM:300 μM), Ado:ZM241385 (500 μM:1 μM), Ado: 
ZM241385:caffeine (500  μM:1  μM:300  μM) or with-
out stimulation were seeded independently to establish 
appropriate controls. The CellTiter 96® AQueous One 
Solution (Promega, Madison, WI, USA) commercial 
kit was used to determine T-cell proliferation accord-
ing to the procedure provided in the supplier insert. 
After incubating the cells for 4 h at 37 °C and 5 % CO2, 
the plate was read on an ELISA plate reader (Corning) 
at a wavelength of 490  nm. The percentage of T-cell 
proliferation was determined as follows: % prolifera-
tion =  [reading T-cell cultures with conditioned media 
and anti-CD2/CD3/CD28 beads]/[reading T-cell cul-
tures with anti-CD2/CD3/CD28 beads] × 100.
Determination of IFN‑γ in activated T‑cells
A total of 2.5 × 105 CD8+ T-cells were cultured for 48 h 
in a 24-well plate (Corning) with 1 ml of IMDM culture 
medium +  10  % dialyzed FBS in the presence of beads 
coated with anti-CD2/CD3/CD28 in the ratio 2:1 and in 
the presence or absence of 20 μL of MSCs supernatants. 
Caffeine (300  μM) or ZM241385 (1  μM) were added to 
some wells. Lymphocytes stimulated with beads coated 
with anti-CD2/CD3/CD28 alone or in the presence of 
synthetic Ado (500 μM), caffeine (300 μM), Ado:caffeine 
(500  μM:300  μM), Ado: ZM241385 (500  mM:1  mM), 
Ado: ZM241385:caffeine (500  μM:1  μM:300  μM) or 
without stimulus were seeded independently to estab-
lish appropriate controls. During the last 4 h of culture, 
Brefeldin-A (Sigma-Aldrich) was added to a final con-
centration of 10  μM to determine the content of intra-
cellular IFN-γ. Subsequently, cells were collected, fixed 
and permeated using the Cytofix/Cytoperm Kit (BD 
Biosciences, San Jose, CA, USA) kit. T-cells were labeled 
with anti-IFN-γ/FITC and anti-CD8/APC (R&D Systems, 
Inc, Minneapolis, MN, USA) monoclonal antibodies, 
incubated for 30 min at 4 °C and washed three times with 
PBS. The labeled cells were evaluated in a CyAN flow 
cytometer (Beckman Coulter). A total of 5 × 104 events 
were acquired to analyze the percentage of CD8+IFN-γ+ 
cells using Summit V4.3 software.
cAMP assay
Measurements of cAMP levels were performed, as 
described previously [40]. Briefly, CD8+ T-cells (4 × 105) 
were cultured alone or in the presence of 20  µl of each 
supernatant (total volume of 200 µl). In other cases, syn-
thetic Ado (500  μM), caffeine (300  μM), Ado:caffeine 
(500  μM:300  μM), Ado: ZM241385 (500  mM:1  mM), 
Ado: ZM241385:caffeine (500 μM:1 μM:300 μM), or the 
ARs agonist, 5′-N-ethylcarboxamidoadenosine (NECA; 
Sigma-Aldrich) (5  μM) were seeded independently to 
establish appropriate controls. The cells were incu-
bated for 30 min at 37 °C, and the reaction was stopped 
by addition of 1 N hydrochloric acid. cAMP levels were 
determined by ELISA using the Parameter™ cAMP assay 
kit (R&D Systems, Inc, Minneapolis, MN, USA).
In vitro analysis of the suppression of effector CTL activity
To analyze the suppressor capacity of Ado on effector 
CTL function, CD8+ T-cells specific for the YMLDLQ-
PETT peptide derived from the E7 HPV-16 protein were 
obtained using a method previously reported by our 
group [41]. A total of 1 × 106 CTLs were previously cul-
tured for 3 h in the presence of synthetic Ado (500 µM) 
or with 20 µl of supernatants obtained from MSCs cul-
tured for 5  h in presence of 5  mM AMP. Subsequently, 
CTLs were washed and challenged with cells from the T2 
lymphoblastic cell line that express empty HLA-A*02:01 
molecules on their cell surfaces [42], which were loaded 
with 10 µM YMLDLQPETT peptide.
Target cells (peptide-loaded T2) were labeled with 
5(6)-carboxyfluorescein diacetate N-succinimidyl ester 
(CFSE) (Sigma-Aldrich), and CTLs were labeled with 
CD8-APC antibody (BD Bioscience) following the pro-
tocol provided by BD Bioscience. The cytotoxic activ-
ity of effector cells on target cells was determined in the 
proportions 10:1, 5:1 and 2.5:1 (effector:target) using 
a cell viability solution (7AAD, Sigma-Aldrich). Viable 
cells were analyzed under a Coulter CyAN flow cytom-
eter (Beckman Coulter) from the acquisition of 100,000 
events by determining the percentage of positive target 
cells for CFSE/7AAD.
Lymphocytes were independently seeded with 
medium alone or medium with AMP, synthetic Ado, 
caffeine (300  μM), ZM241385 (1  μM), Ado:caffeine 
(500  μM:300  μM), Ado:ZM241385 (500  mM:1  mM) 
or Ado: ZM241385:caffeine (500  μM:1  μM:300  μM) to 
establish the appropriate controls. A total of 5 % hydro-
gen peroxide was used in some cases to determine the 
total lysis of target cells.
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The percentage of lysis was calculated according to the 
following formula: % cytotoxicity = 100 × [(experimental 
lysis (CFSE+, 7AAD+) − basal lysis (CFSE+, 7AAD+)/
(total lysis (CFSE+, 7AAD+)  −  basal lysis (CFSE+, 
7AAD+)].
Statistical analysis
All numerical data are presented as the mean 
value  ±  SEM of three independent experiments. Com-
parisons were evaluated by multivariate statistical analy-
sis using GraphPad Prism version 7 (GraphPad Prism 
software, USA). The difference was considered statisti-
cally significant at P < 0.05.
Results
Immunophenotype and differentiation capacity 
of NCx‑MSCs and CeCa‑MSCs
Individual experiments from NCx-MSCs and CeCa-
MSCs displayed immunophenotypes and differentia-
tion capacities similar to those reported previously [19]. 
MSCs from both sources expressed high levels of the 
characteristic MSCs surface markers CD105, CD90, 
and CD73 as established by the International Society 
for Cellular Therapy (ISCT) [2]. Furthermore, the MSCs 
expressed low levels of HLA-ABC, were HLA-DR-nega-
tive and did not express hematopoietic markers such as 
CD34, CD45 and CD14 or endothelial markers such as 
CD31 (Fig.  1A). Meanwhile, MSCs from both sources 
were capable of adipogenic, osteogenic and chondrogenic 
differentiation (Fig. 1B).
Expression and functional activity of CD39 and CD73 
ectonucleotidases in CeCa‑MSCs and NCx‑MSCs
In a hypoxic tumor microenvironment, Ado diminishes 
the ability of effector cells to kill malignant transformed 
cells [43]. The adenosinergic pathway contributes sig-
nificantly to the immunosuppressive capacity of MSCs 
[44, 45]. We analyzed the expression level of CD39 and 
CD73 ectonucleotidases in CeCa-MSCs and NCx-MSCs, 
and we compared their ability to suppress the activa-
tion and effector functions of CD8+ T-cells through the 
production of Ado. CeCa-MSCs exhibited significantly 
(P < 0.05) higher CD39 and CD73 expression levels than 
NCx-MSCs (Fig.  2). Through flow cytometry analysis 
we detected that the mean fluorescence intensity (MFI) 
for CD39 ectonucleotidase was 68 ±  25 in CeCa-MSCs 
and 25 ± 7 in NCx-MSCs, and the MFI value for CD73 
ectonucleotidase was 170 ± 34 in CeCa-MSCs compared 
to 89 ± 24 in NCx-MSCs (Fig. 2a). Similar results were 
observed using immunocytochemical analysis, the total 
expression density (TED) for CD39 ectonucleotidase 
was 1786 ± 189 in CeCa-MSCs and 1146 ± 206 in NCx-
MSCs, and the TED value for CD73 ectonucleotidase 
was 3480 ± 375 in CeCa-MSCs compared to 2189 ± 258 
in NCx-MSCs (Fig. 2b, c).
Furthermore, samples containing 1 ×  105 MSCs were 
cultured in the presence of the adenine nucleotides ATP, 
ADP and AMP at 5  mM to test the ability of MSCs to 
generate Ado through the functional activity of CD39 and 
CD73 ectoenzymes. Aliquots were taken from the super-
natants at 60-min intervals to analyze nucleotide hydrol-
ysis and Ado generation. TLC and UPLC were used for 
this analysis. According to the expression of both ectoen-
zymes found in MSCs membranes, after 300 min of cul-
ture in the presence of different nucleotides, CeCa-MSCs 
more efficiently hydrolyzed ATP, ADP and AMP nucleo-
tides to generate Ado from each nucleotide, as shown (by 
arrows) in the TLC image of the products obtained after 
elution of the samples in TLC (Fig. 3a).
Furthermore, to determine the amount of Ado gen-
erated by MSCs during the culture period with differ-
ent adenine nucleotides, aliquots were taken from the 
supernatants, and Ado production was quantified by 
UPLC. Using synthetic Ado concentrations as reference 
standards (Fig.  3b), the amount of Ado generated by 
CeCa-MSCs during the culture period was significantly 
higher than that produced by the NCx-MSCs (Fig.  3c). 
Ado concentrations in the supernatants of CeCa-MSCs 
cultured for 5 h in the presence of ATP, ADP and AMP 
were 230 ±  35, 320 ±  42 and 1950 ±  216  µM, respec-
tively, whereas respective concentrations of 53.5 ± 12.2, 
42.8 ± 6.5 and 880 ± 184 µM were found in NCx-MSC 
supernatants (Fig.  3c). Moreover, MSCs cultured in the 
absence of nucleotides showed no detectable Ado levels, 
and the addition of POM-1 (specific inhibitor of CD39) or 
APCP (specific inhibitor of CD73) decreased the ability 
of MSCs to hydrolyze the different adenine nucleotides 
by more than 90 % (Fig. 3a, c). In fact, the low Ado con-
centrations produced by MSCs cultured in the presence 
of POM1- or APCP were similar to that obtained when 
mAbs anti-CD39 or anti-CD73 were added to the cell 
cultures (Fig. 3d). Moreover, the addition of nucleotides 
(ATP, ADP and AMP), inhibitors (POM-1 and APCP) or 
mAbs (anti-CD39 or anti-CD73) to the cell cultures, did 
not affect the expression of the CD39 and CD73 ectonu-
cleotidases on MSCs cell surfaces (Fig. 3e). These results 
provide evidence of that Ado produced by MSCs cultures 
in the presence of adenine nucleotides is due to the enzy-
matic activity of CD39 and CD73 on MSCs.
Ado produced by CeCa‑MSCs strongly inhibited the 
proliferation and activation of CD8+ T‑cells
Ado inhibits the activation and cytotoxic effector func-
tions of both NK cells and CD8+ T-cells [32, 38]. CD8+ 
T-cells were isolated by negative selection from PBMCs 
from normal donors to determine if the Ado generated 
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by MSCs was able to inhibit the proliferation and acti-
vation of effector T-cells. These isolated CD8+ T-cells 
were cultured for 72 h with beads containing anti-CD2/
CD3/CD28 antibodies. This incubation was carried out 
in the presence of different concentrations of synthetic 
Ado (32–1000  μM) and supernatants obtained from 
NCx-MSCs and CeCa-MSCs precultured with adenine 
nucleotides. Caffeine (300  μM), a nonselective inhibi-
tor of the ARs, was added in some cultured plates. In 
other cases, ZM241385 (1  µM), a selective antagonist 
of the A2A receptor, was added. As shown in Fig.  4a, 
when using synthetic Ado, the inhibition of CD8+ T-cell 
Fig. 1 Functional characterization of mesenchymal stromal cells (MSCs) from normal cervix (NCx‑MSCs) and cervical cancer (CeCa‑MSCs). A 
Immunophenotype of MSCs cells. Cells were stained with FITC, PE or APC‑conjugated monoclonal antibodies against surface markers indicated or 
immunoglobulin isotype control antibodies. Cells were analyzed using flow cytometry. Representative histograms for the indicated cell markers are 
shown. B MSCs from the two sources (NCx and CeCa) were cultured in the adipogenic, osteogenic and chondrogenic induction medium for 14, 21, 
and 28 days, respectively. (a) and (d) Adipogenic differentiation was indicated by accumulation of neutral lipid vacuoles that stained with Oil Red 
O. Scale bar 100 µm (magnification ×20). (b) and (e) Osteogenic differentiation was indicated with alkaline phosphatase staining. Scale bar 100 µm 
(magnification ×20). (c) and (f) Chondrogenic differentiation was indicated by the chondrogenic matrix colored by Alcian blue in cryosections from 
pelleted micromass. Scale bar 100 µm (magnification ×20). One representative experiment is showed
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proliferation was proportional to the increase in the con-
centration of synthetic Ado added to T-cell cultures. An 
inhibition of proliferation of 50–60 % was found at Ado 
concentrations of 62–250 μM. At concentrations higher 
than 500 μM, inhibition was greater than 80 % (Fig. 4a). 
NCx-MSC supernatants cultured in the presence of 
AMP, inhibited the proliferation of CD8+ T-cells by 
approximately 40  %, whereas supernatants from CeCa-
MSCs doubled their inhibitory capacity, as shown (by 
bars with diagonal lines) in (Fig.  4b). The Ado concen-
tration in CD8+ T-cell cultures was approximately 250 
and 600  μM when adding NCx-MSC and CeCa-MSC 
supernatants, respectively. These concentrations were 
maintained in subsequent assays. Furthermore, CeCa-
MSC supernatants cultured for 5  h in the presence of 
ATP and ADP inhibited CD8+ T-cell proliferation by 
approximately 30–40  %, as shown by (bars in grey and 
black) in (Fig. 4b). With supernatants derived from NCx-
MSCs, the inhibition was less than 10 % (Fig. 4b). Moreo-
ver, the inhibitory effect on CD8+ T-cell proliferation 
was significantly blocked by adding caffeine (300 μM) or 
ZM241385 (1 μM) to CD8+ T-cell cultures in the pres-
ence of MSC supernatants, suggesting that the inhibition 
of CD8+ T-cell proliferation was due to the presence of 
Ado in the supernatants (Fig. 4b).
To analyze the effect of Ado on CD8+ T-cell activation, 
these cells were stimulated with beads containing anti-
CD2/CD3/CD28 antibodies in the presence or absence 
of synthetic Ado or supernatants from MSCs previ-
ously cultured with AMP. After culturing cells for 48 h, 
we determined the percentage of CD8+IFN-γ+ T-cells. 
Approximately 19  ±  5  % CD8+IFN-γ+ T-cells were 
obtained by stimulating CD8+ T-cells in the presence 
of activation beads. However, 7.3 ±  % of CD8+IFN-γ+ 
T-cells were obtained when synthetic Ado (500  μM) 
was added to cultured CD8+ T-cells. The percentage of 
CD8+IFN-γ+ T-cells obtained in the presence of NCx-
MSC supernatant was 13 ± 2.5 % and in the presence of 
CeCa-MSC supernatant was 6 ± 1.5 % (Fig. 5). Interest-
ingly, the addition of caffeine, the antagonist ZM241385, 
or both ARs antagonists, to CD8+ T-cell cultures 
strongly blocked the inhibitory effect of CD8+ T-cell 
activation produced by MSCs supernatants, suggesting 
that Ado generated in CeCa-MSC supernatants strongly 
inhibits the activation of CD8+ T-cells (Fig. 5).
Moreover, we observed that Ado generated in CeCa-
MSCs supernatants was able to suppress the activation of 
CD8+ T cells. Thus, the addition of CeCa-MSCs super-
natants to CD8+ T cells, induced a strong increase in the 
level of cAMP in these cells compared with the basal one, 
interestingly this effect was blocked by the addition of 
ZM241385, caffeine or both AR antagonists (Fig. 6).
The Ado generated by the CeCa‑MSCs strongly inhibits the 
effector function of CTLs
The previously reported [40, 46] CTL activation and 
CTL cytotoxic activity measurement system, was used to 
determine whether Ado generated by CeCa-MSCs affects 
the effector capacity of CTLs. CD8+ T-cells specific for 
the antigenic peptide YMLDLQPETT from the sequence 
11–20 of the HPV-16 E7 protein with specific affinity 
to the HLA-A*0201 allele, were cultured for 3  h in the 
Fig. 2 Expression of CD39 and CD73 in NCx‑MSCs and CeCa‑MSCs. 
The expression of CD39 and CD73 ectonucleotidases was determined 
in NCx‑MSC (n = 5) and CeCa‑MSC (n = 5) cell membranes by flow 
cytometry analysis (a) and by immunocytochemical analysis (b, c) 
as described in “Methods” section. The arrows indicate typical cells 
stained with human anti‑CD39 and anti‑CD73 mAbs. The mean 
fluorescence intensity (MFI) ± SEM of 10,000 events (a), and the 
total expression density (TED) evaluated by digital pathology using 
the Aperio CS system (c) are shown. Secondary antibody alone was 
included as control (Ctl) for the experiments. The images were taken 
at ×20 magnification (Scale bar 100 µm). Asterisk indicates significant 
differences (P < 0.05) compared to NCx‑MSCs
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presence of synthetic Ado or supernatants obtained from 
MSCs cultured for 5 h in the presence of 5 mM AMP and 
subsequently challenged against T2 target cells (HLA-
A*0201+) loaded with peptide YMLDLQPETT. As a 
positive control of inhibition, CTLs were incubated in the 
presence of synthetic Ado (500  μM). As expected, syn-
thetic Ado significantly inhibited the cytotoxic capacity 
of CTLs (Fig.  7a). Furthermore, only CeCa-MSC super-
natants comparably inhibited the cytotoxic activity of 
CTLs (Fig. 7b), whereas CTLs cultured in the presence of 
NCx-MSC supernatants showed no inhibitory effect on 
the cytotoxic activity of CTLs (Fig. 7c). Interestingly, the 
addition of either caffeine or ZM241385, or the mixture 
of both, to CTL cultures in the presence of synthetic Ado 
Fig. 3 Hydrolytic activity of CD39 and CD73 ectonucleotidases expressed in MSCs. A total of 1 × 105 CEMs derived from NCx‑MSCs (n = 5) and 
CeCa‑MSCs (n = 5) were cultured at 37 °C with 5 mM adenine nucleotides (ATP, ADP or AMP) in the presence or absence of POM‑1 (specific CD39 
inhibitor) or APCP (specific CD73 inhibitor). a Adenosine produced by the hydrolysis of nucleotides was analyzed by thin layer chromatography 
(TLC). The ATP, ADP and AMP hydrolysis products (marked with arrows) at the end of MSC culture with different nucleotides are shown. ATP, ADP, 
AMP, inosine (Ino) and synthetic adenosine were used as markers. b Adenosine contained in supernatant samples was quantified every 60 min by 
ultra‑performance liquid chromatography (UPLC), using standard concentrations of synthetic Ado (upper). A representative linear range between 
concentration and histogram integral area for Ado is shown (lower). c The concentration of Ado produced by the hydrolysis of ATP (upper), ADP 
(middle) and AMP (lower) during the period of MSC culture with the respective nucleotides is shown. Asterisk indicates significant (P < 0.001) differ‑
ences compared to NCx‑MSCs. d The concentrations of Ado produced by the hydrolysis of adenine nucleotides (ATP, ADP or AMP) after 5 h of cul‑
ture of MSCs in the presence of either ectonucleotidase specific inhibitors (POM‑1 or APCP) or human mAbs (anti‑CD39 and anti‑CD73) are shown. 
Asterisk indicates significant (P < 0.001) differences compared to the either CD39 or CD73 basal expression. e The expression of the CD39 and CD73 
ectonucleotidases on MSCs cultured during 5 h alone with culture medium (CM) or in the presence of nucleotides (ATP, ADP and AMP), inhibitors 
(POM‑1 and APCP) and mAbs (anti‑CD39 or anti‑CD73) is shown. Data are representative of three independent experiments, and the mean ± SEM 
are shown
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(Fig.  7a) or CeCa-MSC supernatants (Fig.  7b) strongly 
blocked the inhibitory effect of Ado on cytotoxic CTL 
activity. Culturing CTLs in the presence of AMP did not 
affect their effector activity (data not shown).
Our results strongly suggested that the differential 
expression of CD39 and CD73 ectonucleotidases on the 
membranes of CeCa-MSCs compared to NCx-MSCs may 
have an important role in the immunosuppressive capac-
ity of the CTL-mediated anti-tumor immune response 
through the generation of Ado.
Discussion
MSCs were described in the early 1970s in the context 
of regenerative medicine based on their plasticity to dif-
ferentiate into chondrogenic, adipogenic and osteogenic 
lineages [47]. However, various immunosuppressive 
properties of MSCs have recently been described, pav-
ing the way for the use of MSCs in immune disorders 
such as graft versus host disease and multiple sclerosis 
[48]. Several studies have focused on elucidating MSCs 
involvement in malignancy development through the 
Fig. 4 Adenosine generated by CeCa‑MSCs strongly inhibits the proliferation of CD8+ T‑cells. A total of 5 × 105 CD8+ T‑cells obtained by negative 
selection were cultured with beads containing anti‑CD2/CD3/CD28 antibodies in a 2:1 ratio and in the presence of various concentrations of syn‑
thetic adenosine (a). Some cells were cultured with supernatants (Sup) obtained from NCx‑MSC or CeCa‑MSC cultured in the presence of the AMP 
(bars with diagonal lines), ADP (grey bars) or ATP (black bars), or in the presence of adenine nucleotides plus 300 μM caffeine (CAF), a nonselective 
antagonist of Ado receptors; 1 µM ZM241385 (ZM), a selective antagonist of A2A receptor, or CAF:ZM (300 μM:1 µM), as indicated (b). CD8+ T‑cells 
cultured in the presence of 500 μM synthetic Ado were used as positive controls of inhibition. After 96 h of culture, CD8+ T‑cell proliferation was 
determined by a colorimetric method described in “Methods” section. Significant differences *(P < 0.05) and **(P < 0.01) were obtained compared 
with CD8+ T‑cells cultured with beads in the absence of Ado (negative control of inhibition). Data are representative of three independent experi‑
ments, and the mean ± SEM are shown
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generation of tumors of mesenchymal origin and in the 
evasion and suppression of the immune system through 
several mechanisms that have not been fully elucidated 
[13, 20]. In the present study, we demonstrated that 
increased CD39 and CD73 expression in CeCa-MSCs 
allows these cells to rapidly generate Ado from the ade-
nine nucleotides ATP, ADP and AMP, thereby exerting a 
strong immunosuppressive capacity on the proliferation, 
activation and effector functions of CTLs. In contrast, 
NCx-MSCs only generated Ado from AMP due to the 
low expression of CD39 in the membrane. In a hypoxic 
tumor microenvironment, Ado production is mainly 
mediated by the expression of CD39 and CD73 ectonu-
cleotidases in hematopoietic and non-hematopoietic 
cells, including endothelial cells, immunosuppressive 
regulatory T-cells, mononuclear myeloid cells and tumor 
cells [43]. The ability of CeCa-MSCs to catalyze the ATP, 
ADP and AMP nucleotides and to generate immuno-
suppressive Ado suggests that CeCa-MSCs are part of a 
non-hematopoietic cell population that can significantly 
contribute to the generation of an immunosuppressive 
microenvironment. The high CD39 and CD73 expression 
found in CeCa-MSCs contrasts with results obtained by 
Saldanha-Araujo et  al. [23] and Kerkelä et  al. [24], who 
reported that both BM-MSCs and UCB-MSCs express 
high levels of CD73 and low levels of CD39 on their sur-
face, enabling them to quickly generate Ado from AMP 
but not from ATP. However, both studies showed that 
the addition of activated T-cells to their culture system 
allowed the generation of Ado from ATP due to the high 
CD39 expression on activated T-cells, suggesting a co-
operative functional activity between MSCs and acti-
vated T-cells in the inflammatory microenvironment to 
generate Ado from ATP released in the damaged tissue 
[23, 24]. Therefore, our results suggest that CeCa-MSCs 
in association with cervical tumor cells, which according 
to Maldonado et al. [49] and Mello et al. [50] are part of 
the tumor microenvironment in CeCa, can contribute 
significantly to the generation of Ado in the presence of 
high levels of ATP [49, 50].
Furthermore, adenosine produced in the tumor micro-
environment inhibits the innate and adaptive immune 
response. The inhibitory effects of Ado on the effector 
cells of the immune system are mainly induced through 
the A2A and A2B receptors, which couple to G-proteins 
and induce an increase in cAMP levels, reducing the pro-
duction of proinflammatory cytokines and increasing 
the synthesis of Th2-type cytokines and pro-angiogenic 
factors such as VEGF [32]. In our study, the prolifera-
tion and production of IFN-γ+ by CD8+ T-cells acti-
vated with anti-CD3/CD2/CD28 antibodies and the 
CTL antigen-specific effector capacity, were inhibited in 
a dose-dependent manner by Ado generated by MSCs. 
Supernatants from CeCa-MSCs contained approxi-
mately 2  mM Ado and had an inhibitory effect higher 
than 80  %, comparable to that observed when similar 
concentrations of synthetic Ado were added to cul-
tures of activated CD8+ T-cells. In contrast, Ado levels 
in the NCx-MSC supernatants were less than 600  μM, 
with an inhibition below 20 % when added to T-cell cul-
tures. Moreover, the use of A2A receptor antagonists 
was shown in recent studies to promote the anti-tumor 
effector activity of CTLs through a perforin-dependent 
mechanism, suggesting that adenosine signaling through 
A2A receptors inhibits the production of cytolytic gran-
ules by CTLs [51, 52]. Additionally, the antagonism of 
A2A an A2B receptors inhibits metastatic progression to 
lung in a murine model of breast cancer and is depend-
ent on TCD8+IFN-γ+ activated T-cells, indicating that 
Ado signaling through these receptors also plays a role 
in the inhibition of effector T-cell activation [53]. In our 
study, we also provide evidence of that immunosuppres-
sive activity of Ado contained in CeCa-MSCs superna-
tants can be through A2A receptors on CD8+ activated 
T cells. This is because to the fact the increased level of 
cAMP induced in activated CD8+ T cells by the addi-
tion of CeCa-MSCs supernatants was blocked (>80  %) 
Fig. 5 Adenosine generated by CeCa‑MSCs strongly inhibits CD8+ 
T‑cell activation. A total of 5 × 105 CD8+ T‑cells obtained by negative 
selection were cultured with beads containing anti‑CD2/CD3/CD28 
antibodies in a 2:1 ratio and in the presence of supernatants (Sup) 
obtained from NCx‑MSC or CeCa‑MSC cultures. Some cells were 
cultured in the presence of 300 μM caffeine (CAF), a nonselective 
antagonist of Ado receptors, or 1 µM ZM241385 (ZM), a selective 
antagonist of A2A receptor, and combinations of these antago‑
nists, as indicated. CD8+ T‑cells cultured in the presence of 500 μM 
synthetic Ado were used as positive controls of inhibition. After 
96 h of culture, the CD8+IFN‑γ+ T‑cell percentage was determined. 
Significant differences *(P < 0.05) and **(P < 0.01) were obtained 
compared with CD8+ T‑cells cultured with beads in the absence of 
Ado (negative control of inhibition). Data are representative of three 
independent experiments, and the mean ± SEM are shown
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by ZM241385 (selective antagonist of A2A receptor) or 
caffeine (adenosine analog and unspecific blocker of Ado 
receptors). This strongly suggests that CeCa-MSCs can 
participate significantly in the immunosuppression of 
the anti-tumor immune response through the purinergic 
pathway.
Based on our findings, we propose that the differen-
tial expression of CD39 and CD73 ectonucleotidases in 
CeCa-MSCs and NCx-MSCs, and therefore the different 
capacities to generate Ado, are the result of MSCs con-
ditioning in the tumor microenvironment during the 
course of the disease. There is substantial evidence that 
BM-MSCs can migrate to the tumor, thus contributing 
not only to the formation of tumor stroma but also to 
the generation of an anti-inflammatory and immunosup-
pressive microenvironment [13]. For example, a study of 
ovarian cancer reported that 60–70 % of the cellular con-
tent of tumor stroma consisted of BM-MSCs [5]. Other 
studies have found that TGF-β and SDF-α cytokines as 
well as CXCR6 are important mediators of the migra-
tion of BM-MSCs to the tumor microenvironment [54]. 
Furthermore, the expression of CD39 and CD73 in the 
tumor microenvironment may be regulated by intrin-
sic physiological factors. For example, a hypoxic tumor 
microenvironment can promote the expression of CD73, 
as hypoxia-inducible factor-1α (HIF-1α) interaction with 
its binding site (hypoxia response element, HRE) in the 
CD73 gene promoter promotes CD73 expression [55]. 
The involvement of TGF-β in the regulation of CD39+ 
and CD73+ expression in various immunosuppressive 
cell types has also been reported. For example, CD73 
expression in immunosuppressor CD4+ T-cells in mice 
was mainly induced by TGF-β [56]. In other studies, 
both myeloid suppressor cells in mouse tumors [33] and 
suppressor Th17 cells [57] were induced to co-express 
high levels of CD39 and CD73 via signaling mediated 
by TGF-β, therefore producing Ado as an immunosup-
pressive mechanism. Persistent infection with HR-HPV 
is associated with the production of immunosuppressive 
cytokines such as IL-10 and TGF-β, which increase in 
proportion to the degree of disease progression [35–37]. 
Therefore, we can hypothesize that the TGF-β produced 
during the development of CeCa may condition resident 
MSC populations or MSCs that may have migrated from 
the bone marrow into the tumor site to co-express high 
levels of CD39 and CD73 ectonucleotidases. In previous 
studies, we found that CeCa-MSCs induce the CeCa-
derived CaSki and HeLa cell lines to increase synthe-
sis of both IL-10 and TGF-β and to decrease expression 
of HLA class I molecules in the membrane, protecting 
Fig. 6 Adenosine contained in CeCa‑MSC supernatants strongly increases the cAMP levels in CD8+ T cells. CD8+ T‑cells (4 × 105) previously 
stimulated with beads containing anti‑CD2/CD3/CD28 antibodies in a 2:1 ratio, were cultured during 30 min in the presence of supernatants 
(Sup) obtained from NCx‑MSC or CeCa‑MSC cultures. In other cases, cells cultured in the presence of synthetic Ado (500 μM), caffeine (300 μM), 
Ado:caffeine (500 μM:300 μM), Ado: ZM241385 (500 mM:1 mM), Ado: ZM241385:caffeine (500 μM:1 μM:300 μM), or the ARs agonist, 5′‑N‑ethylcar‑
boxamidoadenosine (NECA; Sigma‑Aldrich) (5 μM) were seeded independently to establish appropriate controls. cAMP levels of the CD8+ T cells 
were determined as indicated in “Methods” section. Significant differences *(P < 0.05) and **(P < 0.01) were obtained compared with CD8+ T‑cells 
cultured with beads in the absence of Ado (negative control of inhibition). Data are representative of three independent experiments, and the 
mean ± SEM are shown
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these cells from immune recognition [19, 46]. Therefore, 
the presence of MSCs in the CeCa tumor microenviron-
ment may favor tumor evasion from immune recognition 
and the immunosuppression of the anti-tumor immune 
response.
Conclusions
This study found that increased expression of CD39 and 
CD73 ectonucleotidases in CeCa-MSC membranes com-
pared to NCx-MSCs was associated with a strong ability 
to generate Ado from the hydrolysis of ATP, ADP and 
AMP nucleotides. In contrast, NCx-MSCs generated 
Ado from only AMP due to the low expression of CD39 
in the NCx-MSC membranes. Interestingly, the amount 
of Ado generated by CeCa-MSCs cultured in the pres-
ence of adenine nucleotides significantly increased cAMP 
levels in activated CD8+ T cells, likewise, inhibited the 
proliferation, activation and effector functions of CD8+ 
antigen-specific T-cells. These results suggest for the first 
time that the CeCa-MSCs present in the tumor microen-
vironment may play an important role in the suppression 
of the anti-tumor immune response in CeCa through the 
purinergic pathway.
Considering that the CD39 and CD73 overexpression 
in tumors has been associated with a worse prognosis 
as well as to chemotherapy resistance in patients with 
several malignances [58], our results contribute in elu-
cidate that the overexpression of CD39 and CD73 on 
CeCa-MSCs may support the immunosuppressive tumor 
microenvironment to inhibit the function of the antitu-
moral effector cells, such as CTLs. In consequence some 
therapeutic strategies should be directed to block or neu-
tralize the functional activity of these ectonucleotidases 
in CeCa.
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Fig. 7 Adenosine generated by CeCa‑MSCs strongly inhibits 
cytotoxic CTL activity. CTLs specific for the antigenic peptide 
YMLDLQPETT from the HPV‑16 E7 protein were cultured for 3 h in the 
presence of synthetic 500 μM Ado (a) or supernatants (Sup) obtained 
from NCx‑MSC or CeCa‑MSC cultures, (b) and (c) respectively, and 
subsequently challenged against T2 cells loaded with the antigenic 
peptide YMLDLQPETT at 10:1, 5:1 and 2.5:1 ratios of effector:target 
cells. Some cells were cultured in the presence of 300 μM caffeine 
(CAF), a nonselective antagonist of Ado receptors, or 1 µM ZM241385 
(ZM), a selective antagonist of A2A receptor. CTLs cultured for 3 h in 
the presence of 500 μM synthetic Ado were used as positive controls 
to analyze the inhibitory effect of Ado on CTL cytotoxic activity. The 
antagonists CAF and ZM were added to some culture media to block 
the inhibitory effect of Ado. The cytotoxic activity of CTLs was deter‑
mined by a cell viability method through a CFSE and 7AAD labeling 
as indicated in “Methods” section. Significant differences *(P < 0.05) 
and **(P < 0.01) were obtained compared with the cytotoxic activity 
of CTLs cultured in absence of Ado. Data are representative of three 
independent experiments, and the mean ± SEM are shown
Page 13 of 14de Lourdes Mora‑García et al. J Transl Med  (2016) 14:302 
Author details
1 Immunobiology Laboratory, Cellular Differentiation and Cancer Unit, 
FES‑Zaragoza, UNAM, Mexico City, Mexico. 2 Immunology and Cancer Labora‑
tory, Oncology Research Unit, Oncology Hospital, National Medical Center, 
IMSS, Mexico City, Mexico. 3 Mesenchymal Stem Cells Laboratory, Oncology 
Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico 
City, Mexico. 4 School of Medicine, UNAM, Mexico City, Mexico. 5 Oriente 170 
No. 160 Colonia Moctezuma 2a Sección Delegación Venustiano Carranza, 
15530 Mexico City, Mexico. 
Acknowledgements
We thankfully acknowledge the excellent technical assistance of Luis Alberto 
Vallejo UDIBI, IPN), María del Carmen Fuentes Castañeda and Juan de Dios 
Moreno Álvarez (Oncology Research Unit, Oncology Hospital, National Medi‑
cal Center, IMSS).
Competing interests
The authors declare that they have no competing interests.
Funding
We are indebted for CONACYT support to AMG (Grants 106591 and 240635) 
and DGAPA‑PAPIIT support to MLMG (Grant Nos. IN217013 and IN226516); and 
Mexican Institute of Social Security, IMSS, support to AMG (Grants Nos. 762, 
1014 and 1258) are gratefully acknowledged.
Received: 2 June 2016   Accepted: 10 October 2016
References
 1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. 
Multilineage potential of adult human mesenchymal stem cells. Science. 
1999;284:143–7.
 2. Dominici M, Le Blanc K, Mueller I, Slaper‑Cortenbach I, Marini F, Krause 
D, et al. Minimal criteria for defining multipotent mesenchymal stromal 
cells. The International Society for Cellular Therapy position statement. 
Cytotherapy. 2006;8:315–7.
 3. Gregory CA, Prockop DJ, Spees JL. Non‑hematopoietic bone marrow 
stem cells: molecular control of expansion and differentiation. Exp Cell 
Res. 2005;306:330–5.
 4. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characteriza‑
tion, differentiation, and application in cell and gene therapy. J Cell Mol 
Med. 2004;8:301–16.
 5. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, et al. Origins of the 
tumor microenvironment: quantitative assessment of adipose‑derived 
and bone marrow‑derived stroma. PLoS One. 2012;7:e30563.
 6. Sun Z, Wang S, Zhao RC. The roles of mesenchymal stem cells in tumor 
inflammatory microenvironment. J Hematol Oncol. 2014;7:14.
 7. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–5.
 8. Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential 
of mesenchymal stem cell‑derived extracellular vesicles. Proteomics. 
2013;13:1637–53.
 9. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, et al. Mesen‑
chymal stem cells display coordinated rolling and adhesion behavior on 
endothelial cells. Blood. 2006;108:3938–44.
 10. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. CCR2‑dependent 
recruitment of macrophages by tumor‑educated mesenchymal stromal 
cells promotes tumor development and is mimicked by TNFα. Cell Stem 
Cell. 2012;11:812–24.
 11. Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, et al. Effects of inflamma‑
tory factors on mesenchymal stem cells and their role in the promotion 
of tumor angiogenesis in colon cancer. J Biol Chem. 2011;286:25007–15.
 12. Kabashima‑Niibe A, Higuchi H, Takaishi H, Masugi Y, Matsuzaki Y, Mabuchi 
Y, et al. Mesenchymal stem cells regulate epithelial–mesenchymal 
transition and tumor progression of pancreatic cancer cells. Cancer Sci. 
2013;104:157–64.
 13. Johann PD, Muller I. Multipotent mesenchymal stromal cells: possible 
culprits in solid tumors? Stem Cells Int. 2015;2015:914632.
 14. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. Human ovarian 
carcinoma‑associated mesenchymal stem cells regulate cancer stem 
cells and tumorigenesis via altered BMP production. J Clin Investig. 
2011;121:3206–19.
 15. Wulling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in 
giant cell tumor of bone. Hum Pathol. 2003;34:983–93.
 16. Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu‑Ebinger S, Kluba 
T, et al. Tumour stromal cells derived from paediatric malignancies 
display MSC‑like properties and impair NK cell cytotoxicity. BMC Cancer. 
2010;10:501.
 17. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. 
Stem‑like cells in bone sarcomas: implications for tumorigenesis. Neopla‑
sia. 2005;7:967–76.
 18. Cao H, Xu W, Qian H, Zhu W, Yan Y, Zhou H, et al. Mesenchymal stem 
cell‑like cells derived from human gastric cancer tissues. Cancer Lett. 
2009;274:61–71.
 19. Montesinos JJ, Mora‑Garcia Mde L, Mayani H, Flores‑Figueroa E, Garcia‑
Rocha R, Fajardo‑Orduna GR, et al. In vitro evidence of the presence 
of mesenchymal stromal cells in cervical cancer and their role in 
protecting cancer cells from cytotoxic T cell activity. Stem Cells Dev. 
2013;22:2508–19.
 20. Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape 
from immune system: role of mesenchymal stromal cells. Immunol Lett. 
2014;159:55–72.
 21. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of 
CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell‑lympho‑
cyte interaction. Haematologica. 2007;92:881–8.
 22. Di Trapani M, Bassi G, Ricciardi M, Fontana E, Bifari F, Pacelli L, et al. Com‑
parative study of immune regulatory properties of stem cells derived 
from different tissues. Stem Cells Dev. 2013;22:2990–3002.
 23. Saldanha‑Araujo F, Ferreira FI, Palma PV, Araujo AG, Queiroz RH, Covas 
DT, et al. Mesenchymal stromal cells up‑regulate CD39 and increase 
adenosine production to suppress activated T‑lymphocytes. Stem Cell 
Res. 2011;7:66–74.
 24. Kerkela E, Laitinen A, Rabina J, Valkonen S, Takatalo M, Larjo A, et al. Aden‑
osinergic immunosuppression by human mesenchymal stromal cells 
requires co‑operation with T cells. Stem Cells. 2016;34:781–90.
 25. Sattler C, Steinsdoerfer M, Offers M, Fischer E, Schierl R, Heseler K, et al. 
Inhibition of T‑cell proliferation by murine multipotent mesenchymal 
stromal cells is mediated by CD39 expression and adenosine generation. 
Cell Transplant. 2011;20:1221–30.
 26. Ohta A, Sitkovsky M. Role of G‑protein‑coupled adenosine receptors in 
downregulation of inflammation and protection from tissue damage. 
Nature. 2001;414:916–20.
 27. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A 
adenosine receptor protects tumors from antitumor T cells. Proc Natl 
Acad Sci USA. 2006;103:13132–7.
 28. Bruzzese L, Fromonot J, By Y, Durand‑Gorde JM, Condo J, Kipson N, et al. 
NF‑κB enhances hypoxia‑driven T‑cell immunosuppression via upregula‑
tion of adenosine A(2A) receptors. Cell Signal. 2014;26:1060–7.
 29. Linden J, Cekic C. Regulation of lymphocyte function by adenosine. 
Arterioscler Thromb Vasc Biol. 2012;32:2097–103.
 30. Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL. Adeno‑
sine production by human B cells and B cell‑mediated suppression of 
activated T cells. Blood. 2013;122:9–18.
 31. Apasov S, Koshiba M, Redegeld F, Sitkovsky MV. Role of extracellular 
ATP and P1 and P2 classes of purinergic receptors in T‑cell develop‑
ment and cytotoxic T lymphocyte effector functions. Immunol Rev. 
1995;146:5–19.
 32. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and 
inflammation. Trends Mol Med. 2013;19:355–67.
 33. Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P, et al. Role 
of TGF‑beta signaling in generation of CD39+ CD73+ myeloid cells in 
tumors. J Immunol. 2014;193:3155–64.
 34. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of 
antitumor immune responses. Trends Immunol. 2012;33:231–7.
 35. Alcocer‑Gonzalez JM, Berumen J, Tamez‑Guerra R, Bermudez‑Morales 
V, Peralta‑Zaragoza O, Hernandez‑Pando R, et al. In vivo expression of 
immunosuppressive cytokines in human papillomavirus‑transformed 
cervical cancer cells. Viral Immunol. 2006;19:481–91.
Page 14 of 14de Lourdes Mora‑García et al. J Transl Med  (2016) 14:302 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 36. Bermudez‑Morales VH, Gutierrez LX, Alcocer‑Gonzalez JM, Burguete A, 
Madrid‑Marina V. Correlation between IL‑10 gene expression and HPV 
infection in cervical cancer: a mechanism for immune response escape. 
Cancer Investig. 2008;26:1037–43.
 37. Torres‑Poveda K, Bahena‑Roman M, Madrid‑Gonzalez C, Burguete‑Garcia 
AI, Bermudez‑Morales VH, Peralta‑Zaragoza O, et al. Role of IL‑10 and 
TGF‑β1 in local immunosuppression in HPV‑associated cervical neoplasia. 
World J Clin Oncol. 2014;5:753–63.
 38. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in 
cancer. Oncogene. 2010;29:5346–58.
 39. Grunewald JK, Ridley AJ. CD73 represses pro‑inflammatory responses in 
human endothelial cells. J Inflamm. 2010;7:10.
 40. Apasov SG, Chen JF, Smith PT, Schwarzschild MA, Fink JS, Sitkovsky MV. 
Study of A(2A) adenosine receptor gene deficient mice reveals that 
adenosine analogue CGS 21680 possesses no A(2A) receptor‑unrelated 
lymphotoxicity. Br J Pharmacol. 2000;131:43–50.
 41. Mora‑Garcia Mde L, Duenas‑Gonzalez A, Hernandez‑Montes J, De la 
Cruz‑Hernandez E, Perez‑Cardenas E, Weiss‑Steider B, et al. Up‑regulation 
of HLA class‑I antigen expression and antigen‑specific CTL response in 
cervical cancer cells by the demethylating agent hydralazine and the 
histone deacetylase inhibitor valproic acid. J Transl Med. 2006;4:55.
 42. Hosken NA, Bevan MJ. Defective presentation of endogenous antigen by 
a cell line expressing class I molecules. Science. 1990;248:367–70.
 43. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer‑derived adeno‑
sine: new therapeutic approaches. Cancer Discov. 2014;4:879–88.
 44. Chen X, Shao H, Zhi Y, Xiao Q, Su C, Dong L, et al. CD73 pathway 
contributes to the immunosuppressive ability of mesenchymal 
stem cells in intraocular autoimmune responses. Stem Cells Dev. 
2016;25:337–46.
 45. El Omar R, Xiong Y, Dostert G, Louis H, Gentils M, Menu P, et al. Immu‑
nomodulation of endothelial differentiated mesenchymal stromal cells: 
impact on T and NK cells. Immunol Cell Biol. 2016;94:342–56.
 46. Garcia‑Rocha R, Moreno‑Lafont M, Mora‑Garcia ML, Weiss‑Steider B, Mon‑
tesinos JJ, Pina‑Sanchez P, et al. Mesenchymal stromal cells derived from 
cervical cancer tumors induce TGF‑β1 expression and IL‑10 expression 
and secretion in the cervical cancer cells, resulting in protection from 
cytotoxic T cell activity. Cytokine. 2015;76:382–90.
 47. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa 
SF, Luria EA, et al. Precursors for fibroblasts in different populations of 
hematopoietic cells as detected by the in vitro colony assay method. Exp 
Hematol. 1974;2:83–92.
 48. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, 
et al. Application of multipotent mesenchymal stromal cells in pediatric 
patients following allogeneic stem cell transplantation. Blood Cells Mol 
Dis. 2008;40:25–32.
 49. Maldonado PA, Pimentel VC, Negrini LA, Morsch VM, Schetinger MR. Role 
of the purinergic system in patients with cervical intraepithelial neoplasia 
and uterine cancer. Biomed Pharmacother. 2012;66:6–11.
 50. Mello Pde A, Filippi‑Chiela EC, Nascimento J, Beckenkamp A, Santana DB, 
Kipper F, et al. Adenosine uptake is the major effector of extracellular ATP 
toxicity in human cervical cancer cells. Mol Biol Cell. 2014;25:2905–18.
 51. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extra‑
cellular adenosine A2A purinergic receptor‑mediated signaling in murine 
T cells. J Biol Chem. 1997;272:25881–9.
 52. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor 
cells impairs antitumor T‑cell responses: a novel mechanism of tumor‑
induced immune suppression. Cancer Res. 2010;70:2245–55.
 53. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B 
receptor blockade slows growth of bladder and breast tumors. J Immu‑
nol. 2012;188:198–205.
 54. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone 
marrow‑derived myofibroblasts contribute to the mesenchymal stem cell 
niche and promote tumor growth. Cancer Cell. 2011;19:257–72.
 55. Gao ZW, Dong K, Zhang HZ. The roles of CD73 in cancer. Biomed Res Int. 
2014;2014:460654.
 56. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold 
SP, et al. Generation of anti‑inflammatory adenosine by leukocytes is 
regulated by TGF‑β. Eur J Immunol. 2011;41:2955–65.
 57. Martin F, Apetoh L, Ghiringhelli F. Controversies on the role of Th17 in 
cancer: a TGF‑β‑dependent immunosuppressive activity? Trends Mol 
Med. 2012;18:742–9.
 58. Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G. Anti‑CD73 in 
cancer immunotherapy: awakening new opportunities. Trends Cancer. 
2016;2:95–109.
